| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. | Blood | 2005 | 6.07 |
| 2 | Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. | Blood | 2011 | 1.23 |
| 3 | Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis. | Pediatr Blood Cancer | 2013 | 0.80 |
| 4 | Renal amyloidosis in a child with sickle cell anemia. | Pediatr Nephrol | 2006 | 0.79 |
| 5 | Concomitance of idiopathic myelofibrosis and amyloidosis. | Hematol Oncol Stem Cell Ther | 2010 | 0.75 |
| 6 | Management of life-threatening hemorrhages and unsafe interventions in nonhemophiliac children by recombinant factor VIIa. | Clin Appl Thromb Hemost | 2008 | 0.75 |
| 7 | Correlation of clinical phenotype with a pericentric inversion of chromosome 9 and genetic counseling. | Saudi Med J | 2008 | 0.75 |